Page 1264 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPter 90 Vaccines 1225

23. Roestenberg M, de Vlas SJ, Nieman AE, et al. Efficacy of preerythrocytic 49. Vogt TM, Wise ME, Bell BP, et al. Declining hepatitis A mortality in the
and blood-stage malaria vaccines can be assessed in small sporozoite United States during the era of hepatitis A vaccination. J Infect Dis
challenge trials in human volunteers. J Infect Dis 2012;206:319–23. 2008;197:1282–8.
24. Gaynes RP. Germ Theory: Medical Pioneers in Infectious Diseases: ASM 50. Marin M, Zhang JX, Seward JF. Near elimination of varicella deaths in
Press; 2011. the US after implementation of the vaccination program. Pediatrics
25. Emil von Behring - Facts. Nobel Media. Available at: http:// 2011;128:214–20.
www.nobelprize.org/nobel_prizes/medicine/laureates/1901/ 51. Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent
behring-facts.html. [Accessed 1 August 2016]. dengue vaccine in children in Latin America. N Engl J Med
26. Modlin J, Wenger J. Achieving and maintaining polio eradication–new 2015;372:113–23.
strategies. N Engl J Med 2014;371:1476–9. 52. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts
27. Hagan JE, Wassilak SG, Craig AS, et al. Progress toward polio eradication immunogenicity of the yellow fever vaccine in humans. Nat Immunol
- worldwide, 2014-2015. MMWR Morb Mortal Wkly Rep 2015;64:527–31. 2009;10:116–25.
28. Dowdle WR. The principles of disease elimination and eradication. Bull 53. Li S, Rouphael N, Duraisingham S, et al. Molecular signatures of
World Health Organ 1998;76(Suppl. 2):22–5. antibody responses derived from a systems biology study of five human
29. Enders JF, Robbins FC, Weller TH. Classics in infectious diseases. The vaccines. Nat Immunol 2014;15:195–204.
cultivation of the poliomyelitis viruses in tissue culture by John F. Enders, 54. Mooney M, McWeeney S, Canderan G, et al. A systems framework for
Frederick C. Robbins, and Thomas H. Weller. Rev Infect Dis vaccine design. Curr Opin Immunol 2013;25:551–5.
1980;2:493–504. 55. Kuri-Cervantes L, Fourati S, Canderan G, et al. Systems biology and the
30. Grabenstein JD, Klugman KP. A century of pneumococcal vaccination quest for correlates of protection to guide the development of an HIV
research in humans. Clin Microbiol Infect 2012;18:15–24. vaccine. Curr Opin Immunol 2016;41:91–7.
31. Watson DA, Musher DM, Jacobson JW, et al. A brief history of the 56. Immunization Schedules. US Department of Health and Human Services;
pneumococcus in biomedical research: a panoply of scientific discovery. 2016. Available at: http://www.cdc.gov/vaccines/schedules/hcp/index.html.
Clin Infect Dis 1993;17:913–24. [Accessed 13 February 2016].
32. Swift HF, Wilson AT, Lancefield RC. Typing Group a Hemolytic Streptococci 57. Recommended Adult Immunization Schedule—United States - 2016;
by M Precipitin Reactions in Capillary Pipettes. J Exp Med 1943;78:127–33. 2016. Available at: http://www.cdc.gov/vaccines/schedules/downloads/
33. Hannoun C. The evolving history of influenza viruses and influenza adult/adult-schedule.pdf. [Accessed 13February 2016].
vaccines. Expert Rev Vaccines 2013;12:1085–94. 58. Recommended Immunization Schedules for Persons Aged 0 Through 18
34. Dove A. Maurice Hilleman. Nat Med 2005;11:S2. Years. United States 2016. US Department of Health and Human Services;
35. Plotkin S. History of vaccination. Proc Natl Acad Sci USA 2016. Available at: http://www.cdc.gov/vaccines/schedules/downloads/chil
2014;111:12283–7. d/0-18yrs-child-combined-schedule.pdf. [Accessed 13 February 2016].
36. Avery OT, Goebel WF. Chemo-Immunological Studies on Conjugated 59. WHO recommendations for routine immunization - summary tables;
Carbohydrate-Proteins: Ii. Immunological Specificity of Synthetic 2015. Available at: http://www.who.int/immunization/policy/
Sugar-Protein Antigens. J Exp Med 1929;50:533–50. immunization_tables/en/ [Accessed 6 April 2016].
37. Schneerson R, Barrera O, Sutton A, et al. Preparation, characterization, 60. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the
and immunogenicity of Haemophilus influenzae type b Prevention of HIV-1 Transmission. N Engl J Med 2016;375:830–9.
polysaccharide-protein conjugates. J Exp Med 1980;152:361–76. 61. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection
38. Riedel S. Edward Jenner and the history of smallpox and vaccination. with early antiretroviral therapy. N Engl J Med 2011;365:493–505.
Proc (Bayl Univ Med Cent) 2005;18:21–5. 62. Koester KA, Grant RM. Editorial Commentary: Keeping Our Eyes on the
39. Deria A, Jezek Z, Markvart K, et al. The world’s last endemic case of Prize: No New HIV Infections With Increased Use of HIV Pre-exposure
smallpox: surveillance and containment measures. Bull World Health Prophylaxis. Clin Infect Dis 2015;61:1604–5.
Organ 1980;58:279–83. 63. Global AIDS Update 2016. UN AIDS; 2016. Available at: http://
40. World Health Organization. The Global Eradication of Smallpox: Final www.who.int/hiv/pub/arv/global-AIDS-update-2016_en.pdf. [Accessed 1
Report of the Global Commission for the Certification of Smallpox August 2016].
Eradication, Geneva, December 1979. Geneva, Switzerland: World Health 64. Hammer SM, Sobieszczyk ME, Janes H, et al. Efficacy trial of a DNA/
Organization; 1980. rAd5 HIV-1 preventive vaccine. N Engl J Med 2013;369:2083–92.
41. CDC. Ten great public health achievements–United States, 1900-1999. 65. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/
MMWR Morb Mortal Wkly Rep 1999;48:241–3. Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a
42. Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working G. double-blind, randomised, placebo-controlled test-of-concept phase 2b
Historical comparisons of morbidity and mortality for study. Lancet Infect Dis 2011;11:507–15.
vaccine-preventable diseases in the United States. JAMA 66. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a
2007;298:2155–63. cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind,
43. CDC. Ten great public health achievements–United States, 2001-2010. randomised, placebo-controlled, test-of-concept trial. Lancet
MMWR Morb Mortal Wkly Rep 2011;60:19–23. 2008;372:1881–93.
44. Whitney CG, Zhou F, Singleton J, et al. Benefits from immunization 67. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind,
during the vaccines for children program era - United States, 1994-2013. placebo-controlled efficacy trial of a bivalent recombinant glycoprotein
MMWR Morb Mortal Wkly Rep 2014;63:352–5. 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
45. Potkin A, Orenstein W, Offit PA. Vaccines. 6th ed. Philadelphia, PA: J Infect Dis 2006;194:1661–71.
Saunders; 2013. 68. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial
46. Zipprich J, Winter K, Hacker J, et al. Measles outbreak–California, of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
December 2014-February 2015. MMWR Morb Mortal Wkly Rep J Infect Dis 2005;191:654–65.
2015;64:153–4. 69. Moodie Z, Metch B, Bekker LG, et al. Continued Follow-Up of Phambili
47. Tate JE, Cortese MM, Payne DC, et al. Uptake, impact, and effectiveness Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports
of rotavirus vaccination in the United States: review of the first 3 years of Increased HIV-1 Acquisition among Vaccinated Men. PLoS ONE
postlicensure data. Pediatr Infect Dis J 2011;30:S56–60. 2015;10:e0137666.
48. Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV After 70. Duerr A, Huang Y, Buchbinder S, et al. Extended follow-up
Introduction of the Vaccination Program in the United States. Pediatrics confirms early vaccine-enhanced risk of HIV acquisition and
2016;137:1–9. demonstrates waning effect over time among participants in a